Navigation Links
U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America

PLANO, Texas, May 13 /PRNewswire/ -- U.S. Renal Care, Inc. ("USRC"), a privately-held leading provider of outpatient dialysis services, today announced that it is extending its previously announced cash tender offer, through its wholly owned subsidiary Urchin Merger Sub, Inc., for all outstanding shares of common stock of Dialysis Corporation of America (Nasdaq: DCAI) ("DCA"), until 5:00 p.m., New York City time, on June 1, 2010, unless further extended. The tender offer was previously set to expire at 12:00 midnight, New York City time, on May 19, 2010.

USRC anticipates that on or about May 24, 2010, the conditions set forth in the debt commitment letter, dated as of April 13, 2010, between USRC and Royal Bank of Canada (including the entering into of definitive credit agreements with the lenders) will have been satisfied, other than those customary conditions which by their nature must be satisfied substantially simultaneously with the funding of the financing underlying the debt commitment letter. Accordingly, to comply with applicable rules of the Securities and Exchange Commission, USRC is extending the expiration date of the offer as set forth above, such that five business days remain in the offer following the satisfaction of the financing condition. USRC is filing an amendment to its Schedule TO to reflect this extension of the offer.

Upon the satisfaction of the conditions in the debt commitment letter, USRC will make a further announcement to that effect and will file an amendment to its Schedule TO expressly stating that the applicable conditions specific to the financing set forth in the debt commitment letter have been satisfied. At such time, USRC will ensure that at least five business days remain in the offer, or will extend the offer so that at least five business days remain in the offer.

As of the close of business on May 12, 2010, 2,119,383 shares of DCA common stock had been tendered in and not withdrawn from the offer.

About U.S. Renal Care, Inc.

Founded in 2000 by an experienced team of healthcare executives, U.S. Renal Care, Inc. works in partnership with nephrologists to develop, acquire, and operate outpatient treatment centers for persons suffering from chronic kidney failure, also known as End Stage Renal Disease. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis and peritoneal dialysis services. U.S. Renal Care operates 47 dialysis clinics in Texas and Arkansas. For more information on U.S. Renal Care, Inc. please visit  

Important additional information and where to find it:

This announcement is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of Dialysis Corporation of America.  Investors and shareholders are urged to read both the tender offer statement and the solicitation/recommendation statement regarding the tender offer because they contain important information that holders of Dialysis Corporation of America securities should consider before making any decision regarding tendering their securities.  Urchin Merger Sub, Inc. and U.S. Renal Care, Inc. have filed tender offer materials with the Securities and Exchange Commission, and Dialysis Corporation of America has filed a solicitation/recommendation statement with respect to the offer.  The tender offer materials (including an offer to purchase, a related letter of transmittal and certain other offer documents) and the solicitation/recommendation statement contain important information that should be read carefully before any decision is made with respect to the tender offer.  The offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, are available to all holders of shares of Dialysis Corporation of America at no expense to them.  The tender offer materials and the solicitation/recommendation statement are available free of charge at the Securities and Exchange Commission's web site at  Free copies of these documents may also be obtained by mailing a request to the information agent for the tender offer, Innisfree M&A Incorporated, 501 Madison Avenue, 20th Floor, New York, New York 10022 or by calling toll free at (888) 750-5834 (shareholders) or collect at (212) 750-5833 (banks and brokers).

SOURCE U.S. Renal Care, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
2. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
3. DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin
4. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
6. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
7. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
8. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
9. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
10. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
11. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):